Tesseract Medicines is proud to announce the successful completion of a $20 million seed financing round, aimed at advancing its next-generation targeted therapeutics, Covalent Induced Drug Conjugates. This financing was led by Curie.Bio and Gordian Ventures. Capitalizing on recent advancements in antibody-drug conjugates and covalent inhibitors, Tesseract Medicines is pioneering a novel therapeutic modality designed to exploit cancer-specific intracellular proteins for the targeted delivery of cytotoxic payloads. #adc #covalent #drug
About us
Engineering the Next Generation of Covalent Drugs
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Newton, Massachusetts
- Type
- Privately Held
- Founded
- 2022
Locations
-
Primary
Get directions
55 Chapel Street
Newton, Massachusetts 02458, US